Yıl: 2021 Cilt: 10 Sayı: 3 Sayfa Aralığı: 764 - 769 Metin Dili: İngilizce İndeks Tarihi: 09-02-2022

The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment

Öz:
Social distancing, curfew restrictions, travel restrictions and quarantines were imposed in order to reduce the risk of transmission of SARS-CoV-2. These restrictions have caused a severe reduction in admissions to hospitals. Therefore, with this study, we aimed to investigate effect of the COVID-19 pandemic on treatment processes and adherence to therapy of the patients that require to receive omalizumab due to chronic urticaria and to address effect of the pandemic on anxiety level of this patient group. Among the patients who were being followed-up for chronic urticaria and receiving omalizumab for this, files of the patients were examined retrospectively. These patients were applied a mini survey and a validated coronavirus anxiety index. Ninety-eight patients (Female: 65; Male: 33) were recruited in the study. The patients’ 3-month adherence to therapy during March-April-May 2020 was 42.9%. It was the lowest during April (56.1%). The curfew (51%) and the fear of contracting SARS-CoV-2 (50%) were the most common reasons. Although rates of admissions to emergency department, an increase in symptoms of urticaria and need for an additional treatment were higher in the patients with chronic urticaria who were nonadherent to omalizumab therapy, this difference was not statistically significant (p: 0.113, p: 0.216, p: 0.141, respectively). During the pandemic, patients’ adherence to therapy has reduced due to both government-related and patient-related reasons. For patients with chronic urticaria, their adherence to therapy should be ensured by minimizing the risk of transmission of SARS-CoV-2. Furthermore, in order to enhance adherence to therapy of this patient group and make access to health institutions easier, it should be considered for these patients to provide some tolerances and privileges in pandemic-related restrictions.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Ahn DG, Shin HJ, Kim MH, et al. Current status of Epidemiology, diagnosis, therapeutics, and vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30:313-24.
  • Atayık E, Aytekin G. SARS-CoV-2 in a patient with persistent asthma taking omalizumab: The first case in Turkey. 2020;18:23-6.
  • Guner R, Hasanoglu I, Aktas F. COVID-19: Prevention and control measures in community. Turk J Med Sci. 2020;50(SI-1):571-7.
  • Talan L, Altıntaş ND. COVID-19 and intensive care. 2020;18:15-8.
  • Anteby R, Zager Y, Barash Y, et al. The impact of the coronavirus disease 2019 outbreak on the attendance of patients with surgical complaints at a tertiary hospital emergency department. J Laparoendosc Adv Surg Tech A. 2020;30:1001-7.
  • De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383:88-8.
  • Jeffery MM, D'Onofrio G, Paek H, et al. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 pandemic in the US. JAMA Intern Med. 2020;180:1328-33.
  • Ojetti V, Covino M, Brigida M, et al. Non-COVID diseases during the pandemic: Where have all other emergencies gone? Medicina (Kaunas). 2020 1;56.
  • Ozturk AB, Baccioglu A, Soyer O, et al. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol. 202015:1-4.
  • Saini SS, Kaplan AP. Chronic Spontaneous urticaria: The Devil's Itch. J Allergy Clin Immunol Pract. 2018;6:1097-106.
  • Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol. 2016;34:190-200.
  • Westby EP, Lynde C, Sussman G. Chronic urticaria: Following practice guidelines. Skin Therapy Lett. 2018;23:1-4.
  • Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-414.
  • Bi̇cer I, Cakmak C, Demi̇r H, et al. Koronavirus anksiyete olcegi kisa formu: Turkce gecerlik ve guvenirlik calismasi. 2020;25(Special Issue on COVID 19):216-25.
  • Dubey S, Biswas P, Ghosh R, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14:779-88.
  • Giorgi G, Lecca LI, Alessio F, et al. COVID-19-related mental health effects in the workplace: A narrative review. Int J Environ Res Public Health. 2020;17.
  • Diaz Perez D, Lorente Sorolla M, Gonzalez Lago S, et al. [Impact of the SARS-CoV-2 pandemic on the use of the emergency department and admissions in a tertiary hospital]. An Pediatr (Barc). 2020;26.
  • Lazzerini M, Barbi E, Apicella A, et al. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020;4:10-1.
  • Hincapie MA, Gallego JC, Gempeler A, et al. Implementation and usefulness of telemedicine during the COVID-19 pandemic: A scoping review. J Prim Care Community Health. 2020;11:2150132720980612.
  • Ayhan E, Ozturk M, An I, et al. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021;60:253-4.
  • Criado PR, Criado RFJ, Pincelli TP, et al. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: Rapid and excellent response to omalizumab. Int J Dermatol. 2020;59:1294-5.
APA Aytekin G, ATAYIK E (2021). The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. , 764 - 769.
Chicago Aytekin Gökhan,ATAYIK EMEL The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. (2021): 764 - 769.
MLA Aytekin Gökhan,ATAYIK EMEL The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. , 2021, ss.764 - 769.
AMA Aytekin G,ATAYIK E The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. . 2021; 764 - 769.
Vancouver Aytekin G,ATAYIK E The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. . 2021; 764 - 769.
IEEE Aytekin G,ATAYIK E "The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment." , ss.764 - 769, 2021.
ISNAD Aytekin, Gökhan - ATAYIK, EMEL. "The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment". (2021), 764-769.
APA Aytekin G, ATAYIK E (2021). The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. Medicine Science, 10(3), 764 - 769.
Chicago Aytekin Gökhan,ATAYIK EMEL The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. Medicine Science 10, no.3 (2021): 764 - 769.
MLA Aytekin Gökhan,ATAYIK EMEL The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. Medicine Science, vol.10, no.3, 2021, ss.764 - 769.
AMA Aytekin G,ATAYIK E The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. Medicine Science. 2021; 10(3): 764 - 769.
Vancouver Aytekin G,ATAYIK E The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment. Medicine Science. 2021; 10(3): 764 - 769.
IEEE Aytekin G,ATAYIK E "The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment." Medicine Science, 10, ss.764 - 769, 2021.
ISNAD Aytekin, Gökhan - ATAYIK, EMEL. "The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment". Medicine Science 10/3 (2021), 764-769.